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THROMBOSIS AND HEMOSTASIS
Sensitive and selective detection of free FXIII activation peptide: a potential
marker of acute thrombotic events
Elisabeth Ortner,1 Verena Schroeder,1 Reto Walser,2 Oliver Zerbe,2 and Hans P. Kohler1,3
1Department of Hematology, Hemostasis Research Laboratory, University Hospital Bern, Inselspital, Bern; 2Institute of Organic Chemistry, University of Zurich,
Zurich; and 3Department of Internal Medicine, Spital Netz Bern Hospitals, Ziegler Tiefenau, Bern, Switzerland
Coagulation factor XIII (FXIII) stabilizes
fibrin fibers and is therefore a major player
in the maintenance of hemostasis. FXIII is
activated by thrombin resulting in cleav-
age and release of the FXIII activation
peptide (AP-FXIII). The objective of this
study was to characterize the released
AP-FXIII and determine specific features
that may be used for its specific detec-
tion. We analyzed the structure of bound
AP-FXIII within the FXIII A-subunit and
interactions of AP-FXIII by hydrogen
bonds with both FXIII A-subunit mono-
mers. We optimized our previously devel-
oped AP-FXIII ELISA by using 2 monoclo-
nal antibodies. We determined high
binding affinities between the antibodies
and free AP-FXIII and demonstrated spe-
cific binding by epitope mapping analy-
ses with surface plasmon resonance and
enzyme-linked immunosorbent assay. Be-
cause the structure of free AP-FXIII had
been characterized so far by molecular
modeling only, we performed structural
analysis by nuclear magnetic resonance.
Recombinant AP-FXIII was largely flexible
both in plasma and water, differing signifi-
cantly from the rigid structure in the
bound state. We suggest that the recog-
nized epitope is either occluded in the
noncleaved form or possesses a struc-
ture that does not allow binding to the
antibodies. On the basis of our findings,
we propose AP-FXIII as a possible new
marker for acute thrombotic events.
(Blood. 2010;115(24):5089-5096)
Introduction
Blood coagulation is a highly regulated process and plays a major role in
hemostasis. Upon vessel injury, a concerted action of platelets and
plasmatic coagulation stop bleeding and trigger repair of the damaged
vessel. Blood coagulation factor XIII (FXIII) is the last factor to be
activated in the coagulation cascade and its active form functions as a
transglutaminase, which covalently cross-links fibrin polymers and
antifibrinolytic proteins such as 2-plasmin inhibitor to fibrin.1 Because
of its function to stabilize fibrin clots, FXIII plays a major role in acute
thrombotic events such as myocardial infarction, ischemic stroke, deep
vein thrombosis, and pulmonary embolism.2-6
In plasma the inactive FXIII zymogen consists of 2 catalytic
A-subunits and 2 carrier B-subunits forming the FXIII-A2B2
tetramer, which is bound to fibrinogen in physiologic conditions.
During activation of plasma FXIII, thrombin cleaves off the
N-terminal activation peptide (AP-FXIII), which is subsequently
released into plasma,7 and FXIII is thereby converted to FXIII-
A2B2. Binding of Ca2 ions induces the dissociation of the A- and
B-subunits, which is enhanced by the presence of fibrin. Finally,
the A-subunits assume their active configuration (FXIII-A*).1
The Val34Leu polymorphism within AP-FXIII has been associ-
ated with a protective effect against myocardial infarction, deep
venous thrombosis, and ischemic stroke. With an allele frequency
of approximately 25%, this polymorphism is common in the white
population compared with a rather low percentage in the African or
Asian population.1
Crystal structure analysis of the FXIII-A2 homodimer suggests
that the N-terminal AP-FXIII crosses the FXIII-A2 homodimer
interface and occludes the catalytic cavity, preventing substrate
binding to the zymogen.8 Hence it was postulated that either the
release or significant conformational changes of the AP-FXIII are
necessary to expose the catalytic site. In contrast, the authors9 of
another crystallographic study of the FXIII A2-homodimer pro-
posed that AP-FXIII retains its conformation after thrombin
cleavage and remains bound to the FXIII A2-homodimer in the
same position as within the inactive zymogen. More evidence for
the release of AP-FXIII came from our previous study,7 where we
detected free AP-FXIII in plasma and serum. We also suggested
structural changes of free AP-FXIII compared with the bound state
by ab initio modeling and molecular dynamics simulations.
Here, we investigated for the first time the structure of free
AP-FXIII by the use of nuclear magnetic resonance (NMR). We
demonstrate that free AP-FXIII is much more flexible than in its
rigidly bound form. This unique feature allows selective detection
of the cleaved peptide. We used 2 mouse monoclonal antibodies
raised against synthetic AP-FXIII to optimize the enzyme-linked
immunosorbent assay (ELISA) for selective detection of free
AP-FXIII. We characterized the interactions between antibodies
and AP-FXIII by surface plasmon resonance (SPR). Both antibod-
ies bind to free AP-FXIII with very high affinities, and binding was
not significantly influenced by the Val34Leu polymorphism. Fur-
thermore, we identified nonoverlapping binding epitopes for the
2 antibodies and observed no cross-reactivity with the FXIII-A2B2
tetramer or other plasma proteins. Finally, NMR analysis of
15N-labeled recombinant AP-FXIII in water and in plasma proved
the peptide to be largely unstructured. Taken together, our data
demonstrate that AP-FXIII released into plasma can be selectively
detected. We propose that this might be used as a new diagnostic
marker for acute thrombotic events.
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Methods
Contacts of AP-FXIII within the FXIII A-subunit dimer
The conformation of AP-FXIII when still attached to the FXIII A-subunit
was analyzed by use of the coordinates from the 2.1 Å crystal structure,10
protein database entry 1F13 (http://www.rcsb.org/pdb). Positions of amino
acids 1-4 and 37-38 were not resolved in the crystal structure. Visualization
of the FXIII A-subunit dimer and analysis of interactions of AP-FXIII
residues with surrounding amino acids was performed with the Swiss PDB
Viewer,11 version 4.0.1.
Antibodies and peptides
Mouse monoclonal antibody mAb-6B11 against human AP-FXIII was
developed in collaboration with GENOVAC GmbH. For immunization,
a synthetic AP-FXIII was generated according to the published sequence
(Swiss-Prot entry P00488) with an additional cysteine residue at its
N-terminus (CSETSRTAFGGRRAVPPNNSNAAEDDLPTVELQGVVPR) and
coupled to the carrier protein keyhole limpet hemocyanin. After immunization
and subcloning, the monoclonal antibody (immunoglobulin G1) was purified by
the use of a protein-G affinity column, and its purity was verified by sodium
dodecyl sulfate polyacrylamide gel electrophoresis. The production of the mouse
monoclonal antibody mAb-1286 raised against human AP-FXIII was previously
described.7 Synthetic peptides corresponding to full-length AP-FXIII with an
additional N-terminal Cys and containing either Val or Leu at position 34
(AP-FXIII-Val and AP-FXIII-Leu) were produced by ABGENT Inc. AP-FXIII
fragments AP1 to AP9, AP1-12, AP3-12, and AP13-37 were obtained from
GenScript Corp.
AP-FXIII ELISA analyses
We optimized the previously published sandwich-type ELISA7 by using the
2 monoclonal anti-AP-FXIII antibodies mAb-6B11 and mAb-1286 with the
latter biotinylated. In brief, 96-well microtiter plates (Maxisorp; Nunc)
were coated with 100 L of mAb-6B11 at 4 g/mL in coating buffer
(50mM sodium carbonate, pH 9.6). AP-FXIII was diluted in dilution buffer
(50mM Tris-HCl, 150 mM NaCl, 0.1% bovine serum albumin, 0.01%
sodium azide, pH 7.5) and was loaded in a volume of 100 L per well. The
detection antibody mAb-1286 was used at 2 g/mL in dilution buffer
(50mM Tris-HCl, 150mM NaCl, 0.1% bovine serum albumin, pH 7.5),
which was followed by incubation with streptavidin conjugated with
alkaline-phosphatase (Fluka Chemie GmbH, a Sigma-Aldrich company) at
1 g/mL in dilution buffer for 1 hour. Plates were developed with
p-nitrophenyl phosphate (1 mg/mL in 1M diethanolamine containing
0.5mM MgCl2, pH 9.8; Sigma-Aldrich) for exactly 15 minutes. The
color-developing reaction was stopped with 4M NaOH, and optical density
(OD) was measured on a microplate reader at 405 nm with a reference filter
at 550 nm (Anthos HT3; Anthos Labtec Instruments). We tested the ability
of the ELISA to detect native AP-FXIII by analyzing serum samples diluted
1:200 in dilution buffer. To test for cross-reactivity with nonactivated
FXIII-A2 we captured purified FXIII-A2 using a polyclonal antibody and
detected with both monoclonals and a polyclonal as positive control.
Determination of binding affinity and epitope mapping with
SPR
We used a Biacore X system (Biacore) on the basis of SPR12 to measure
binding affinities between AP-FXIII and the antibodies mAb-6B11 and
mAb-1286 and for epitope mapping. In brief, the antibodies were immobi-
lized on the surface of carboxy-methylated dextran sensor chips (CM5;
Biacore) through amine coupling. The surface was activated with a 1:1
mixture of N-hydroxysuccinimide and 1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide hydrochloride (amine-coupling kit; Biacore). The antibody
mAb-6B11 was injected at a concentration of 20 g/mL and mAb-1286 at
50 g/mL in 10mM sodium acetate, pH 5.0, at a flow rate of 10 L/min.
The immobilization reaction was stopped with ethanolamine after the signal
had increased by 14 000 resonance units (RU) for mAb-6B11 and by 11 000
RU for mAb-1286.
For determination of the binding affinity and for epitope mapping, the
peptides were injected at concentrations increasing from 2.5 to 17nM in
HBS-EP buffer (0.01M HEPES [N-2-hydroxyethylpiperazine-N-2-ethane-
sulfonic acid], pH 7.4; 0.15M NaCl; 3mM EDTA [ethylenediaminetetraace-
tic acid]; 0.005% vol/vol surfactant P20) at a flow rate of 10 L/min. After
passage of each peptide, the surface was regenerated by injection of 10 to
20mM NaOH at a flow rate of 10 L/min. Data were analyzed by the global
fitting algorithm of the BIAevaluation 3.0 software package (Biacore).
Epitope mapping analyses by ELISA
Peptides were directly coated onto 96-well DNA-BIND plates (Corning
Inc) at a concentration of 40 g/mL in dilution buffer in a volume of
100 L per well. After blocking (50mM Tris-HCl, 150mM NaCl,
1% bovine serum albumin, pH 7.5), the plates were incubated with either
mAb-6B11 or mAb-1286 at a final concentration of 2 g/mL in dilution
buffer, followed by incubation with a secondary goat anti-mouse alkaline-
phosphatase conjugated antibody (1 g/mL in dilution buffer; Sigma-
Aldrich). Detection was carried out as described previously.
To exclude competition between the 2 antibodies, binding of one
antibody to AP-FXIII was studied in the presence of the other. ELISA
plates were coated with AP-FXIII at concentrations of 0.4 to 137nM and
incubated either with biotinylated mAb-1286 at 2 g/mL only or in a
mixture with mAb-6B11 at 1, 2, or 4 g/mL. Then, the plates were
incubated with a secondary goat anti-mouse alkaline-phosphatase
conjugated antibody (1 g/mL). Detection was performed as described
previously.
Expression of 15N-Ub-AP-FXIII in Escherichia coli for NMR
analyses
We expressed 15N-labeled AP-FXIII as a fusion protein with ubiquitin
according to the method of Kohno et al.13 To obtain the AP-FXIII DNA
construct, 2 overlapping primers (forward 5-TCAGAAACTTCCAGGAC-
CGCCTTTGGAGGCAGAAGAGCAGTTCCA CC CAATAACTCTAAT-
GCAGCGGAAGATGAC-3, reverse 5-CGCGTCGACTATCAC CGGGG-
CACCAAGCCCTGAAGCTCCACTGTGGGCAGGTCATCTTCCG-
CTGCATTAGA-3), which contained an additional SalI site and 2 stop
codons, were amplified by polymerase chain reaction (PCR). This PCR
product was used as template in a second PCR reaction to phosphorylate
the 5-end (forward primer 5-phospho-TCAGAAACTTCCAG-
GACCG-3, reverse 5-CGCGTCGACTATCACCGG-3). In preparation
for cloning into a pUBK19 vector downstream of the ubiquitin sequence,
the AP-FXIII DNA construct was digested with SalI (Fermentas). The
vector plasmid was linearized by digestion with Mph1103I (Fermentas),
and the blunt ends were generated by T4 DNA polymerase (Invitrogen)
followed by digestion with SalI. The AP-FXIII DNA construct was ligated
with the vector plasmid to generate the pUBK19-AP-FXIII plasmid.
A detailed description of the expression and purification process of
AP-FXIII can be found in the supplemental Methods (available on the
Blood Web site; see the Supplemental Materials link at the top of the online
article). In brief, pUBK19-AP-FXIII was transformed into E coli C41
cells,14 which were grown on minimal medium by the use of 15NH4Cl as the
sole nitrogen source. The ubiquitin-AP-FXIII fusion protein was purified by
Ni-NTA chromatography.
AP-FXIII was liberated from its fusion partner through treatment with
yeast ubiquitin hydrolase, and the peptide was finally purified by high-
performance liquid chromatography. The mass of the purified peptide was
verified by electrospray ionization mass spectrometry (data not shown).
Circular dichroism spectroscopy
Circular dichroism spectra were recorded by the use of 50M peptide
solutions in buffer (20mM 2-[N-morpholino]ethanesulfonic acid, pH 5.5, or
sodium phosphate, pH 7) on a Jasco J-715 spectrometer at room tempera-
ture in a quartz cuvette with a 1-cm path length. Spectra were recorded
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covering a range from 190 to 250 nm at a scanning rate of 50 nm/min. Data
from 15 scans were averaged to obtain the spectra.
NMR spectroscopy
Spectra were recorded with 1mM samples of uniformly 15N-labeled
AP-FXIII dissolved in water or plasma at pH 5.5. The proton-nitrogen
correlation map was assigned by the use of standard 3D 15N-resolved Total
Correlation Spectroscopy and nuclear overhauser enhancement spectroscopy
experiments.15,16 15N-NOE values were recorded by the use of a 1H-detected
version of the 15N{1H}-steady state heteronuclear Overhauser effect experi-
ment.17 Spectra were processed in TOPSPIN 2.1 (Bruker) and transferred to the
XEASY18 and CARA19 program packages for data evaluation.
Statistical analysis
Results from replicate experiments were analyzed by descriptive statistics
with Microsoft Office Excel 2007. Results are shown as mean and standard
deviation. Concentration curves used to characterize the ELISA were drawn
in SigmaPlot 10 (Systat Software Inc). Symbols represent mean values, and
error bars represent SD.
Results
Structural analysis of AP-FXIII bound to the FXIII A-subunit
AP-FXIII is part of the FXIII A-subunit and consists of the first
N-terminal 37 amino acids. X-ray crystallography of zymogen
FXIII-A2 demonstrated that AP-FXIII tightly associates with
residues of the FXIII A-subunit.8 As shown in Figure 1A and B,
AP-FXIII is located on the surface of the A-subunit adjacent to the
-sandwich domain. Its N-terminus overlaps with the barrel 1
domain of the other monomer. Figure 1C shows possible interac-
tions with several amino acids of both monomers. We identified
13 hydrogen-bonds (H-bonds) with residues of the same and
4 H-bonds with residues of the other monomer (Figure 1D). The
former include Asn17-Arg107, Asn17-Tyr108, Asn17-Leu249,
Asn18-Arg252, Asn20-Lys156, Ala21-Asp243, Glu23-Arg174
(2 H-bonds), Asp24-Arg158, Pro27-Arg171, Thr28-Arg171, Glu30-
Val169, and Gln32-Tyr167. The latter include Gly10-Thr561,
Arg11-Asp343 (2 H-bonds), and Arg11-Pro399. In addition,
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Catalytic 
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Figure 1. Localization, molecular structure, and interactions of the AP-FXIII within the FXIII A-subunit dimer. (A) Overview of the FXIII A-subunit dimer. The 2 monomers
are shown in yellow and pink with their respective AP-FXIII highlighted in orange and dark pink. (B) Detailed picture of the AP-FXIII of monomer 1. The peptide backbone is
shown as an orange ribbon with carbon, nitrogen, and oxygen atoms colored in white, blue, and red, respectively. The position of Val34 of the common Val34Leu polymorphism
is indicated in light blue. At the N-terminus of the AP-FXIII, amino acids 1-4 are missing, and the gap at the C-terminus represents the missing amino acids 37 and 38.
(C) Immediate molecular environment of the AP-FXIII. All amino acid residues on monomer 1 (green space-filled atoms) and on monomer 2 (pink space-filled atoms) that lie
within 5 Å from the amino acid residues of the AP-FXIII (ball-and-stick atoms) are shown. (D) H-bonds between amino acid residues of the AP-FXIII and surrounding amino acid
residues are shown as dashed lines. H-bonds are drawn if the distance between H-donor and H-acceptor atoms is less than 3.2 Å. Only amino acid residues forming H-bonds
are displayed. Amino acid residues of the AP-FXIII are labeled in orange, the residues of monomers 1 and 2 are labeled in green and pink, respectively.
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3 H-bonds are formed within AP-FXIII: Ser19-Ala21, Ser19-
Ala22, and Gln32-Gly33.
Characterization of the optimized ELISA for free AP-FXIII
We optimized our AP-FXIII–specific ELISA7 by using the mouse
monoclonal antibodies mAb-6B11 and mAb-1286 for capture and
detection, respectively. In a first step, we demonstrated that the
optimized ELISA measures AP-FXIII over a concentration range
between 0.5 and 0.05 ng/mL (0.12nM-12pM; Figure 2A). Next we
evaluated whether the common Val34Leu polymorphism influ-
ences the detection of AP-FXIII. The results indicate that both
variants are detected equally (Figure 2B). We performed further
ELISA analyses to rule out any cross-reactivity with FXIII-
deficient plasma, nonactivated normal plasma, and purified FXIII-
A2. No unspecific binding was detected, and we did not find any
cross-reactivity of the monoclonal antibodies with FXIII-A2 (data
not shown), suggesting that the ELISA is selective for free
AP-FXIII. In serum samples from 3 healthy donors we detected on
average 313.3 ng/mL (41.5 ng/mL SD), corresponding approxi-
mately to the plasma concentration of FXIII tetramer.
Analysis of the binding of both antibodies to free AP-FXIII
We used SPR to investigate the binding characteristics of mAb-
6B11 and mAb-1286 to synthetic AP-FXIII-Val34 and AP-FXIII-
Leu34. Either mAb-6B11 or mAb-1286 was immobilized onto the
sensor chip surface, and binding curves were recorded for both
AP-FXIII variants at 6 different concentrations between 17.5 and
2.5nM. Representative curves for AP-FXIII-Val binding to mAb-
6B11 and to mAb-1286 are shown in Figure 3A and B.
Generally, the sensorgram curves for both antibodies with both
AP-FXIII variants showed no significant dissociation phases. We
also noticed this lack of dissociation during the regeneration of the
chips under very stringent condition. The equilibrium dissociation
constant KD was calculated from the ratio of the measured kinetic
Figure 2. Characterization of the optimized AP-FXIII ELISA. (A) General sensitiv-
ity. Titration of synthetic AP-FXIII in dilution buffer at 0.5, 0.25, 0.125, 0.0625, and
0.03125 ng/mL (0.12 nM-7.8 pM). Mean values from quintuplicates with error bars
representing SD are shown. (B) Evaluation of the sensitivity toward AP-FXIII-
Val34Leu polymorphism. Synthetic AP-FXIII-Val (F) and AP-FXIII-Leu (E) were
titrated at 2.0, 1.0, 0.5, 0.25, 0.125, 0.0625, and 0.03125 ng/mL (0.5 nM-7.8 pM).
Mean values from triplicates with error bars representing SD are depicted.
(C) Competition analysis for mAb-1286 and mAb-6B11. AP-FXIII was detected either
by mAb-1286 only (f), or in a mixture with mAb-6B11 at 1 g/mL ( ), 2 g/mL ( ), or
4 g/mL (). Mean values of triplicates with error bars representing SD are depicted.
Figure 3. Binding affinity of anti-AP-FXIII monoclonal antibodies as measured
by SPR. Sensorgrams of time (seconds) versus RUs are shown. (A) Binding of
AP-FXIII-Val to mAb-6B11. The curves represent the association and dissociation
rates of AP-FXIII-Val at the following concentrations: 2.5 (green), 5 (pink), 7.5 (cyan),
10 (magenta), 12 (dark blue), and 16nM (brown). (B) Binding of AP-FXIII-Val to
mAb-1286 measured at the following concentrations: 5 (magenta), 7.5 (pink),
10 (green), 12.5 (cyan), 15 (dark blue), and 17.5nM brown). (C) Binding affinity data
for mAb-6B11 and mAb-1286 and both AP-FXIII genotypes. The association rate
constant ka, the dissociation rate constant kd and the equilibrium dissociation
constant KD  kd/ka of 2 independent analyses (1st and 2nd) are shown, together with
the average KD and range of variation.
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rate constants kd/ka. KD values obtained for both antibodies with
both AP-FXIII variants are shown in Figure 3C. We found greater
binding affinities for mAb-6B11 compared with mAb-1286. The
affinity did not differ significantly between the 2 AP-FXIII
variants.
Binding site analysis of AP-FXIII by epitope mapping by the use
of SPR
To localize the binding sites of mAb-6B11 and mAb-1286 on
AP-FXIII we performed epitope mapping by using SPR and
ELISA techniques. Figure 4A shows the amino acid sequences of
AP-FXIII and the peptides used for epitope mapping. Peptides
AP1-AP8 were 8 amino acids long and contained 4 overlapping
residues. AP9 differed from AP8 by the Leu substitution at position
34. Additional peptides that were investigated for binding con-
tained either the first 12 amino acids (AP1-12), or amino acids 3 to
12 (AP3-12), or the last 25 amino acids (AP13-37) of AP-FXIII.
In a first step, we measured binding of the short peptides to both
antibodies. These short peptides were tested at a concentration of
10M. Only the peptides AP1 (amino acids 1-8) and AP2 (amino
acids 5-12) bound weakly to mAb-6B11 (Figure 4B). None of the
short peptides showed any affinity toward mAb-1286 (data not
shown). Next, we evaluated the affinity of mAb-6B11 toward the
longer peptides AP1-12, AP3-12, and AP13-37. We measured a KD
of 2.0nM (ka  1.5  105; kd  3.1  104) for AP1-12 and a KD
of 4.2nM (ka  6.6  104; kd  2.8  104) for AP3-12. Figure
4C and D display the sensorgrams of AP1-12 and of AP3-12, from
which the KD for mAb-6B11 was calculated. No binding was
observed with AP13-37, even at the greater concentration of
150nM (Figure 4E). Compared with full-length AP-FXIII (Table
3C) we measured lower affinities of mAb-6B11 toward the
fragments AP1-12 and AP3-12. This difference in KD indicates that
both of these 2 peptides do not contain the whole epitope of
mAb-6B11 because a similar KD would be expected for a complete
epitope. This finding suggests that mAb-6B11 binds to a conforma-
tional epitope that is formed mainly by amino acids within the first
12 amino acids. Although no binding of the fragment AP13-37 was
observed, it could still contain amino acids that contribute to the
formation of the complete epitope but are not sufficient for binding
to mAb-6B11.
Subsequently, binding of the longer peptides AP1-12 and
AP13-37 to mAb-1286 was tested. The sensorgrams revealed much
weaker binding between mAb-1286 and AP13-37 compared with
AP-FXIII and no interaction with AP1-12 (Figure 4F). Further-
more, the sensorgrams showed fast association and weak dissocia-
tion of AP-FXIII with mAb-1286.
Taken together, the results imply that both antibodies recognize
conformational epitopes that do not overlap.
Epitope mapping of AP-FXIII by ELISA
To confirm the SPR results, we also performed epitope mapping by
ELISA. The same peptides as described previously were directly
coated onto microtiter plates and analyzed for binding to mAb-
6B11 and mAb-1286. Table 1 summarizes the results from the
ELISA tests. The antibody mAb-6B11 only recognized AP1 and
AP2 of the 9 short peptides. The longer peptides AP1-12 and
AP3-12 resulted in greater OD signals compared with the signal
obtained for AP2. No binding at all could be detected to AP13-37.
For mAb-1286, we observed no significant binding to AP1-12,
weak binding to peptide AP7, and strong binding to AP13-37
(Table 1). In addition, we performed this ELISA experiment with a
dilution range from 1.6M to 0.1nM and compared OD values for
Figure 4. Epitope mapping with SPR showing sensorgrams of time (seconds) versus RU. (A) Sequences of peptides analyzed for epitope mapping of mAb-6B11 and
mAb-1286. Amino acid sequences of full-length AP-FXIII and all overlapping peptides used for the epitope mapping are depicted. AP8 and AP9 differ in residue 34 containing
either a Val or Leu, respectively. (B) Epitope mapping of mAb-6B11. Peptides AP1-AP9 were tested for binding to mAb-6B11 at a concentration of 10M. All peptides are listed
downward corresponding to their colored curves. (C-D) Affinity analysis of mAb-6B11 to AP1-12 and AP3-12. The affinity of mAb-6B11 to AP1-12 was measured at the following
concentrations: 5 (green), 10 (cyan), 15 (dark blue), 20 (pink), and 30nM (brown) and to AP3-12 at the concentrations: 5 (green), 7.5 (aquamarine), 10 (pink), 15 (cyan), and
20nM (gray). (E) Localization of the binding site of mAb-6B11. mAb-6B11 was tested for binding to AP-FXIII-Val at a concentration of 16nM (purple) and AP13-37 at 150nM
(pink). (F) Localization of the binding site of mAb-1286. The following peptides were tested for binding: AP-FXIII-Val at a concentration of 17.5nM (cyan), and AP13-37 (brown),
and AP1-12 at 30nM (pink).
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AP13-37 with full-length AP-FXIII. The results suggest that
AP13-37 binds to mAb-1286 over a wide concentration range and
even at very low concentrations (data not shown). This finding
supports the conclusion of high-affinity binding of this C-terminal
fragment. Compared with full-length AP-FXIII, however, the
binding affinity was weaker, which may indicate that amino acids
in the C-terminal part are crucial for the formation of a conforma-
tional epitope.
In addition, we verified that mAb-6B11 and mAb-1286 do not
compete with each other for binding to AP-FXIII. As shown in
Figure 2C, there were no significant differences in detection of
AP-FXIII by mAb-1286 in absence or presence of mAb-6B11.
These results are further evidence that the binding sites of
mAb-6B11 and mAb-1286 do not overlap. Taken together, the
results from the epitope mapping analysis by ELISA were in
agreement with the data obtained from our SPR studies.
Analysis of AP-FXIII by NMR
We have determined conformational preferences of recombinant
AP-FXIII in plain water as well as in plasma. The stability of the
AP-FXIII in plasma, however, was insufficient unless the tempera-
ture was lowered to 4°C, where reproducible spectra could be
recorded over a time range of 3 days. NMR experiments were
conducted at pH 5.5 (both in water and in plasma) to reduce
unfavorable amide proton exchange at greater pH that resulted in
broad lines.16 In addition circular dichroism spectra were recorded
at physiologic pH 7.0 and the lower pH 5.5. The data indicate that
neither -helical nor -strand type secondary structural elements
become populated at the greater pH value, although slightly more
polyproline-type absorption at 208 nm occurs at the greater pH
value (data not shown). The [15N,1H]-HSQC spectra of the
AP-FXIII in water revealed the presence of too many peaks, and
the extra peaks were attributed to the presence of cis conformers
about the Pro-peptide bonds. The presence of these additional
peaks already indicated that AP-FXIII in water was mainly
unstructured. The backbone of the AP-FXIII in solution could be
fully assigned in water and to 60% in plasma. We attribute the
lower percentage of assignments to the line-broadening at the
lower temperature and the increased viscosity of the plasma
solution.
To thoroughly investigate whether the AP-FXIII is partially
folded, we decided to use 15N relaxation NMR experiments. The
required 15N-labeled AP-FXIII was produced in milligrams per liter
quantities in E coli biosynthetically from ubiquitin fusion peptides.
To assess whether segments of the polypeptide chain are folded, a
15N{1H}-NOE experiment was recorded. Typically, amide nitrogen
atoms of well-structured regions adopt values larger than 0.5,
whereas for fully flexible regions the values are negative. In our
experience secondary structure can only be reliably determined by
NMR if the H-NOE in the corresponding segment is larger than 0.4.
Values of the 15N{1H}-NOE of AP-FXIII are depicted in Figure 5
for both environments. Clearly, no values larger than 0.4 are
encountered, and for many residues the heteronuclear NOE is close
to 0.2, indicating that they are not fully flexible but that structure
determination using NMR is not possible. Therefore, no in-depth
structural studies were performed.
Discussion
We have previously reported that AP-FXIII is released from the
FXIII A-subunit upon thrombin cleavage and that free AP-FXIII
possibly assumes a different conformation compared with its
bound form.7 The objective of this study was to characterize free
AP-FXIII by 2 novel approaches, which include binding studies
with specific monoclonal antibodies and NMR.
Within the nonactivated FXIII A-subunit dimer, AP-FXIII is
located on the surface of the molecule, and this exposed position
may promote the release of the AP-FXIII from the molecule into
plasma upon activation. A loop containing the thrombin cleavage
site Arg37-Gly38 protrudes from the molecule, making this site
accessible to the protease. The Leu variant of the Val34Leu
polymorphism has been shown to favor the interaction with
thrombin leading to improved activation kinetics.20 The loop as
well as the 4 N-terminal amino acids are flexible and hence not
resolved in the crystal structure. Otherwise, the AP-FXIII assumes
a defined conformation within the FXIII A-subunit dimer. Close
interactions with the molecular environment, in particular 17 H-bonds
between the amino acids of the AP-FXIII and amino acids of its own
monomer as well as with the other monomer may be crucial to maintain
the structure and position of the AP-FXIII within the molecule.
This defined conformation must be altered or lost in free
AP-FXIII because it can be selectively detected by the use of the
optimized AP-FXIII ELISA without any cross-reactivity with
zymogen FXIII-A2B2 present in normal plasma or other plasma
components in FXIII-deficient plasma. We therefore conclude that
the 2 monoclonal antibodies mAb-6B11 and mAb-1286 are specific
Figure 5. 15N{1H}-NOE values of recombinant AP-FXIII in plain aqueous buffer
(blue circles) as well as in plasma (black diamonds) at pH 5.5. No values are
presented in plasma for residues 2 to 5, 7 to 11, 13, 14, 18, 19, 36, and 37 because
those signals could not be assigned.
Table 1. Epitope mapping by ELISA
Peptide OD 405 nm
mAB-6B11
Full-length AP-FXIII (1-37) 	 3.000
AP1 0.054
AP2 1.712
AP1-12 2.625
AP3-12 2.563
AP13-37 0.038
Blank 0.039
mAb-1286
Full-length AP-FXIII (1-37) 	 3.000
AP1-12 0.081
AP3-12 0.121
AP7 0.849
AP13-37 	 3.000
Blank 0.045
Peptides were tested at concentrations of 40M and mean OD values of
duplicates are shown.
ELISA indicates enzyme-linked immunosorbent assay; and OD, optical density.
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for free AP-FXIII. The optimized ELISA also proved sensitive to
detect AP-FXIII at a concentration as low as 12pM. Measurements
in serum confirmed that the ELISA is able to detect native
AP-FXIII.
We further investigated whether the common Val34Leu polymor-
phism influences the detection of the free AP-FXIII. Both antibod-
ies mAb-6B11 and mAb-1286 bound equally well to both AP-
FXIII variants, and binding affinities were not affected by the
Val34Leu polymorphism. Therefore, the described protective effect
of the Val34Leu polymorphism against myocardial infarction, deep
venous thrombosis, and ischemic stroke4,21-27 is most likely only
mediated by structural characteristics of the bound AP-FXIII,
which influence the affinity of thrombin to the bound AP-FXIII.
Epitope mapping analyses suggested that the antibody mAb-
6B11 binds to the N-terminal region of AP-FXIII (amino acids
1-12), whereas the antibody mAb-1286 recognizes the C-terminal
region (amino acids 13-37), and hence the 2 antibodies do not
compete for binding.
For the first time, we conducted a structural analysis of
recombinant AP-FXIII using solution NMR techniques. These
experiments indicated a high conformational flexibility of the
peptide in both water and plasma environments, precluding a more
detailed structural characterization by NMR. However, the relax-
ation data of the peptide in water revealed no experimental
evidence for the presence of a short hairpin, which we previously
proposed on the basis of molecular modeling.7 The finding that the
released peptide is unstructured, as demonstrated by the NMR
studies, suggests that binding to the monoclonal antibodies pro-
ceeds in an induced-fit mode.28 Thus, the specificity of the
antibodies for free AP-FXIII may be explained as follows: the rigid
form of the AP-FXIII bound to FXIII zymogen is incompatible
with this antibody binding mode and/or residues crucial for
antibody recognition are buried within the protein and hence
inaccessible to the antibodies.
In summary, our study confirms that released AP-FXIII can be
distinguished from AP-FXIII bound to zymogen FXIII and can be
detected with a specific and sensitive ELISA. We hypothesize that
detection of AP-FXIII might represent a new diagnostic marker for
acute thrombotic events because the presence of this peptide in
plasma reflects the earlier stage of coagulation. This is in contrast to
the measurement of D-dimer levels, a widely used diagnostic tool
for venous thromboembolism,29 pulmonary embolism,30,31 and
stroke.32,33 D-dimers are clot degradation products and reflect
thrombotic events retrospectively, and their absence is mainly used
to exclude thrombosis. The detection of AP-FXIII might therefore
complement diagnostic strategies for accurate diagnosis of acute
thrombotic events. We also showed that the common Val34Leu
polymorphism does not influence the detection of free AP-FXIII
with respect to affinity and sensitivity toward the antibodies. This
finding presents an important issue because the polymorphism has
a high allele frequency in the white population and could prevent a
possible diagnostic application of the detection of released AP-
FXIII. Although the proof-of-principle has been shown in this
article, clinical studies in patients who experience acute myocardial
infarction, stroke, or venous thromboembolism are needed to
assess the suitability of released AP-FXIII as a marker for acute
thrombotic events.
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